Tuesday, August 22, 2017 6:30:47 PM
I hope so too...
but I've learned to trust the chart and be cautious. with volatile and manipulated small biotech plays.
I like the science, and see no fundamental reason for the take down from 5.50 to 3.33.
but it was achieved. financial manipulation games. I can accept it. but it means Caution must be maintained at all times in my view. for me it means giving up on hoping for rallies before they happen, hoping for great news yet to come and when it comes , what usually happens.... wall street games . I just watch the chart . and expect more games, and volatility in both directions.
Right now, those who bought at 3.33-3.80 looks like it was pretty good. it makes buying now at 4.00-4.10 look ok. and that's all there is to say right now. Resistance overhead from 4.50-5.00 is in play now. to watch and see what it does. how strong will AVXL be to climb thru it. this is a real test now for AVXL to show whether this rally will be true or not. yes it has run from the 3.33 bottom , 1.20 already. but the support zone needs to hold 4.20-4.10 and did so today, so far so good. but its only the first test of 4.20 . there should be more to come .but yes,a good show of strength in the morning to hold 4.20.
its a fair start now for a recovery. took all this time,just to finish this first part, a first rally wave.however high it runs now, after this rally comes a Pullback,that will be the next test after resistance stops the rally. or else the next test might be what wall street does with the September "news cycle" do you anticipate any slam down, like we've had before? I do. I think you have to . so we're not out of any woods just yet,in my view. the support base 3.90-4.30 has to become strong....just like it had to many months ago,. but recently failed. thats the wall street game. always a wall street game to deal with..
but I've learned to trust the chart and be cautious. with volatile and manipulated small biotech plays.
I like the science, and see no fundamental reason for the take down from 5.50 to 3.33.
but it was achieved. financial manipulation games. I can accept it. but it means Caution must be maintained at all times in my view. for me it means giving up on hoping for rallies before they happen, hoping for great news yet to come and when it comes , what usually happens.... wall street games . I just watch the chart . and expect more games, and volatility in both directions.
Right now, those who bought at 3.33-3.80 looks like it was pretty good. it makes buying now at 4.00-4.10 look ok. and that's all there is to say right now. Resistance overhead from 4.50-5.00 is in play now. to watch and see what it does. how strong will AVXL be to climb thru it. this is a real test now for AVXL to show whether this rally will be true or not. yes it has run from the 3.33 bottom , 1.20 already. but the support zone needs to hold 4.20-4.10 and did so today, so far so good. but its only the first test of 4.20 . there should be more to come .but yes,a good show of strength in the morning to hold 4.20.
its a fair start now for a recovery. took all this time,just to finish this first part, a first rally wave.however high it runs now, after this rally comes a Pullback,that will be the next test after resistance stops the rally. or else the next test might be what wall street does with the September "news cycle" do you anticipate any slam down, like we've had before? I do. I think you have to . so we're not out of any woods just yet,in my view. the support base 3.90-4.30 has to become strong....just like it had to many months ago,. but recently failed. thats the wall street game. always a wall street game to deal with..
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
